Table 3.
Response duration in the open‐label extension study per IWG 2006 criteriaa
| Romiplostim n = 34 | |
|---|---|
| Time to first week satisfying criteria,b week | 2·1 (1·1, 3·0) |
| Longest continuous response,c week | 28 (14, 56) |
| Periods ≥8 consecutive weeks satisfying response criteria, n | 1 (1, 3) |
| Total number of weeks satisfying response criteria, n | 37 (17, 126) |
| Percentage of study time meeting response criteria | 86 (77, 93) |
| Dose at first response, μg | 750 (750, 750) |
| Duration of romiplostim treatment, weeks | 44 (23, 160) |
| Not meeting criteria at last platelet count, n (%) | 2 (6·3) |
All data are median (interquartile range [Q1, Q3]) unless otherwise noted.
a
Platelet response was based on International Working Group (IWG) 2006 criteria and was defined as (in the absence of platelet transfusion) an absolute increase of ≥30 × 109/l for patients with an initial platelet count of >20 × 109/l but <100 × 109/l or an increase to >20 × 109/l and by at least 100% for patients with an initial platelet count <20 × 109/l for ≥8 weeks.(Cheson et al, 2006).
b
Time to the first of 8 weeks to establish response.
c
Defined as continuous response per IWG 2006 criteria.